Paclitaxel (Taxol) efficacy in patients with advanced breast cancer resistant to anthracyclines.

No abstract is available for this paper.

• Publication year

  1994

• Venue

  Seminars in Oncology

• Publication date

  1994-10-01

• Fields of study

  Medicine

• Identifiers
  PMID 7939759
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Paclitaxel and recombinant human granulocyte colony-stimulating factor as initial chemotherapy for metastatic breast cancer.

  1993cited by this paper
• Drugs ten years later: epirubicin.

  1993cited by this paper
• Restoration of taxol sensitivity of multidrug-resistant cells by the cyclosporine SDZ PSC 833 and the cyclopeptolide SDZ 280-446.

  1993cited by this paper
• The involvement of a LINE-1 element in a DNA rearrangement upstream of the mdr1a gene in a taxol multidrug-resistant murine cell line.

  1992cited by this paper
• Taxol: the first of the taxanes, an important new class of antitumor agents.

  1992cited by this paper
• Breast cancer: adjuvant therapy with anthracyclines.

  1992cited by this paper
• Evolving concepts in the systemic adjuvant treatment of breast cancer.

  1992cited by this paper
• Hypersensitivity reactions.

  1992cited by this paper
• Transfer and expression of the human multiple drug resistance gene into live mice.

  1992cited by this paper
• Phase II trial of taxol, an active drug in the treatment of metastatic breast cancer.

  1991cited by this paper
• Taxol: twenty years later, the story unfolds.

  1991cited by this paper
• Adjuvant chemotherapy with doxorubicin plus cyclophosphamide, methotrexate, and fluorouracil in the treatment of resectable breast cancer with more than three positive axillary nodes.

  1991cited by this paper
• Primary chemotherapy to avoid mastectomy in tumors with diameters of three centimeters or more.

  1990cited by this paper
• Taxol: a novel investigational antimicrotubule agent.

  1990cited by this paper
• Cancer in the European Community and its member states.

  1990cited by this paper
• Reporting results of cancer treatment

  1981cited by this paper

• The p53 breast cancer tissue biomarker in Indian women.

  2011cites this paper
• Pharmacokinetic analysis of a combined chemoendocrine treatment with paclitaxel and toremifene for metastatic breast cancer

  2009cites this paper
• Phase-II study of weekly schedule of trastuzumab, paclitaxel, and carboplatin followed by a week off every 28 days for HER2+ metastatic breast cancer

  2008cites this paper
• Early Chemotherapy Response Evaluation in Tumors by 99mTc-DTPA-DG

  2008cites this paper
• Metastatic Breast Cancer

  2007cites this paper
• Drug resistance in chemotherapy for breast cancer

  2005cites this paper
• Paclitaxel and Mitoxantrone in Metastatic Breast Cancer: A Phase II Trial of the Italian Oncology Group for Cancer Research

  2004cites this paper
• Activity of first-line epirubicin and paclitaxel in metastatic breast cancer is independent of type of adjuvant therapy

  2004cites this paper
• Weekly paclitaxel as first-line chemotherapy for elderly patients with metastatic breast cancer. A multicentre phase II trial.

  2004cites this paper
• Correlation of p53 status with outcome of neoadjuvant chemotherapy using paclitaxel and doxorubicin in stage IIIB breast cancer.

  2003cites this paper
• Chemotherapy in Breast Cancer

  2002cites this paper
• Phase I Study of Vinorelbine and Carboplatin Combination in Patients with Taxane and Anthracycline Pretreated Advanced Breast Cancer

  2002cites this paper
• A Phase II Study of Genexol(R) (paclitaxel) in Metastatic Breast Cancer.

  2001cites this paper
• Evolution of breast cancer management: Focus on neoadjuvant chemotherapy

  2001cites this paper
• A Phase II Study of Genexol® ( paclitaxel ) in Metastatic Breast Cancer

  2001cites this paper
• High response rate with a lower dose of paclitaxel in combination with cisplatin in heavily pretreated patients with advanced breast carcinoma

  2000cites this paper
• A Phase II Study of Paclitaxel/Cisplatin Combination in Patients with Metastatic Breast Cancer Refractory to Anthracycline-Based Chemotherapy

  2000cites this paper
• Risks and Benefits of Taxanes in Breast and Ovarian Cancer

  2000cites this paper
• Paclitaxel, 5-fluorouracil, and leucovorin (TFL) in the treatment of metastatic breast cancer.

  2000cites this paper
• Current and potential chemotherapeutic agents used for induction chemotherapy in the treatment of breast cancer.

  2000cites this paper
• Initial paclitaxel improves outcome compared with CMFP combination chemotherapy as front-line therapy in untreated metastatic breast cancer.

  1999cites this paper
• The efficacy of chemotherapy with docetaxel and paclitaxel in anthracycline-resistant breast cancer (Review).

  1999cites this paper
• Infusional paclitaxel and weekly vinorelbine chemotherapy with concurrent filgrastim for metastatic breast cancer: high complete response rate in a phase I-II study of doxorubicin-treated patients.

  1999cites this paper
• Dose intensification of mitoxantrone in combination with paclitaxel in advanced breast cancer: a phase II study

  1999cites this paper
• Initial P aclitaxel I mproves O utcome C ompared W ith C MFP Combination C hemotherapy a s F ront-Line T herapy in U ntreated M etastatic B reast C ancer

  1999cites this paper
• Paclitaxel in combination with weekly 24-hour infusional 5-fluorouracil plus leucovorin in the second-line treatment of metastatic breast cancer: results of a phase II study.

  1998cites this paper
• Phase II and pharmacokinetic study of paclitaxel therapy for unresectable hepatocellular carcinoma patients.

  1998cites this paper
• Weekly continuous infusion of 5-fluorouracil with oral leucovorin in metastatic breast cancer patients with primary resistance to doxorubicin

  1998cites this paper
• [Taxanes in the treatment of breast and ovarian cancers: current indications and results].

  1998cites this paper
• [Breast cancer: new therapeutic strategies].

  1998cites this paper
• Italian Breast Cancer Adjuvant Chemo-Hormone Therapy Cooperative Group Trials. GROCTA Trials.

  1998cites this paper
• Fluorouracil-based combinations in the treatment of metastatic breast cancer.

  1998cites this paper
• The addition of paclitaxel to continuous infusion 5-fluorouracil is an active regimen for metastatic breast cancer.

  1998cites this paper
• Managing self-harm: the legal issues

  1997cites this paper
• Australian multicentre phase II trial of paclitaxel in women with metastatic breast cancer and prior chemotherapy

  1997cites this paper
• Paclitaxel Activity in Anthracycline Refractory Breast Cancer Patients

  1997cites this paper
• ▼Paclitaxel and ▼docetaxel in breast and ovarian cancer

  1997cites this paper
• Adjuvant Drug Treatment for Resectable Breast Cancer.

  1997cites this paper
• Paclitaxel (Taxol): a review of its antitumor activity in clinical studies Minireview.

  1996cites this paper
• Paclitaxel (Taxol): mechanisms of Resistance.

  1996cites this paper
• Adjuvant drug therapy for operable breast cancer.

  1996cites this paper
• [Adjuvant chemotherapy of breast cancer].

  1996cites this paper
• Phase I study of paclitaxel and epirubicin in patients with metastatic breast cancer: a preliminary report on safety.

  1996cites this paper
• A phase II study in advanced breast cancer: ZD1694 ('Tomudex') a novel direct and specific thymidylate synthase inhibitor.

  1996cites this paper
• Paclitaxel in metastatic breast cancer: a trial of two doses by a 3-hour infusion in patients with disease recurrence after prior therapy with anthracyclines.

  1995cites this paper
• Taxoids: effective agents in anthracycline-resistant breast cancer.

  1995cites this paper
• Breast Cancer in Older Women

  1995cites this paper
• Nonlinear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic/pharmacodynamic relationships in humans.

  1995cites this paper
• Visual evoked potentials findings in course of paclitaxel doxorubicin combination chemotherapy

  1995cites this paper